Induction therapy for esophageal cancer

Despite advances in treatment, long-term outcomes for esophageal cancer remain poor, with overall survival rates of between 15% and 35%. Poor long-term survival reflects locoregionally advanced disease or metastatic disease at presentation. Among patients undergoing surgical resection, 40% to 50% have stage III disease. Surgery alone results in poor locoregional control and poor long-term outcomes, with survival rates ranging from 10% to 30%. Induction therapy combining surgery with chemotherapy with or without radiotherapy attempts to improve long-term survival in these patients. This article examines the merits of various modalities of induction therapy for patients with locally advanced esophageal cancer.